News
-
-
COMMUNIQUÉ DE PRESSE
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
-
COMMUNIQUÉ DE PRESSE
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
-
-
COMMUNIQUÉ DE PRESSE
Lonza Increases Straight Bond by CHF 150 Million
-
COMMUNIQUÉ DE PRESSE
Lonza Launches Share Buyback Program of up to CHF 2 Billion
-
COMMUNIQUÉ DE PRESSE
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
-
-
COMMUNIQUÉ DE PRESSE
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
-
COMMUNIQUÉ DE PRESSE
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon